Immunologic Therapies Flashcards Preview

Inflammation and Immunity > Immunologic Therapies > Flashcards

Flashcards in Immunologic Therapies Deck (22):
1

Targets B cells by crosslinking DNA inhibiting DNA replication. Used in treating Goodpasture's.

Cyclophosphamide

2

Inhibits TLRs and decreases acidity of lysosomes (retinal toxicity)

Hydroxychloroquine

3

Anti-CD20 Ab. Located on B cells (does not delete plasma cells)--> leads to no Ab production

Rituximab

4

Drug that fuses the extracellular domain of CTLA-4 & Fc region of IgG1. Binds to B7-1/2 and leads to T cell unresponsiveness. Used to manage RA.

Abatacept

5

Anti-PD1

Nivolumab

6

1st line pain reliever, possible hepatotoxicity, Minimal side effects.

Acetominophen

7

IL-1R antagonist

Anakinra

8

Blocks DHFR, increases adenosine and decreases inflammation

Methotrexate

9

COX-1 inhibitors. GI, Renal, and inhibited platelet aggregation risk factors.

Ketorolac and Asprin

10

COX-2 inhibitors; Cardiovascular risks.

Celecoxib and Diclofenac

11

Drug that blocks IL-2 and is used for acute organ rejection.

Daclizumab (Zenapax)

12

Inhibitor of nucleotide synthesis, Inhibits B and T proliferation, Ab synthesis, and NK cell activity. Given to Goodpasture's syndrome patients

Azathioprine (Imuran)

13

TNF inhibitors

a. Infliximab (Remicade)
b. Adalimumab (humira)
c. Etanercept (Enbrel)
d. Certolizumab (Cimzia)
e. Golimumab (Simponi)

14

Ab against Fc portion of IgE. Aids in type I hypersensitivity reaction.

Omalizumab

15

Anti-CTLA 4

Ipilimumab

16

Anti-IL-6 Ab

Tocilizumab

17

Inhibits formation of NFAT by blocking de-phosphorylation of P-NFAT by activated Calcineurin. Used in Stevens Johnson Syndrome

Tacrolimus/Cyclosporine

18

Eliminates fetal RBCs from mom's circulation
Turns off maternal B cells by cross-linking BCR & FcyRII

Rhogam

19

Pyrimidine synthesis blocker and teratogen

Leflunomide

20

Purine synthesis inhibitor

Azathioprine

21

Increases liver production of C1 inhibitor, Treatment of HAE

Danazolol

22

JAK inhibitor, Stops IL-2 autocrine loop that would lead to CD4+ proliferation, differentiation & functionality. Used in RA management

Tofacitinib (Xeljanz)

Decks in Inflammation and Immunity Class (51):